Peer-influenced content. Sources you trust. No registration required. This is HCN.
Hematology Advisor
Advancements in von Willebrand Disease (VWD) treatments, including emicizumab and BT200 (rondoraptivon pegol), are heralding a new age of personalized care, addressing the complex needs of patients with this challenging bleeding disorder.
Hematology February 5th 2024
This BMJ editorial examines whether approaches better equipped to compare rates of menstrual variation in vaccinated versus unvaccinated populations are needed, based on the reports of changes to periods and unexpected vaginal bleeding after vaccination. The US has taken the first step, earmarking $1.67M from the National Institutes of Health to encourage research.
Internal Medicine September 28th 2021